Not only Pfizer won’t work away, they don’t even want to waste time on Covid tool deployment, in other words the Covid screen FDA is not if but when.
1 The scheme was made to shield Pfizer from competitors/3rd party business step in
2 BOD was required to prioritize Covid screen R&D. With Pfizer’s help 1500 ppl data collected at its fastest to do a readout and train algorithms. Probably US trial recruitment has started, thanks to 3m dollars cash injection, and 1m bonus on milestone
3 In case the scheme is voted out, Pfizer still has the remaining R&D in play. They can give up on acquiring 100% of RAP (they underestimated the value of the rest of business), but as long as The Covid license deal can maximize their benefit, they will finally agree with the deal.
I am expecting Sleep check and DX commercialization further down their way after the vote, then we will sit on top of 20.8c (current preferred)+ Covid FDA value.
Hold on another month and vote No!
- Forums
- ASX - By Stock
- RAP
- Ann: Results of First Court Hearing
Ann: Results of First Court Hearing, page-28
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries